111 completed, 18 unknown, 7 not yet recruiting, 7 terminated. 155 Phase 2, 27 Phase 1, 11 Phase 3.
Follow Sebaceous Gland Diseases: new trials by email Literature Review of Sebaceous Gland Diseases trials Research Report on Sebaceous Gland Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne Acne mRNA (messenger ribonucleic acid) vaccine, Placebo - Acne | Phase 2 | Not yet recruiting | Sanofi | 410 | 2026-10-30 | 2026-09-18 |
| Study to Determine Efficacy, Safety, and Tolerability of B244 as a Topical Spray in Subjects With Moderate to Severe Acne Vulgaris B244, Vehicle - Acne Vulgaris | Phase 2 | Not yet recruiting | AOBiome LLC | 176 | 2026-10-01 | 2026-10-08 |
| Comparative Effectiveness of Clindamycin-Retinoid, Clindamycin-Retinoid-Dexamethasone, and 10% SM-hUCMSC Secretome Gel in the Improvement of Mild-to-Moderate Acne Vulgaris Mediklin TR, Solanum Night Cream, Gel Sekretome SM-hUCMSC 10% - Acne Vulgaris | Phase 1 / Phase 2 | Not yet recruiting | Yohanes Firmansyah, dr, MH, MM | 189 | 2026-04-18 | 2026-04-01 |
| Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study Spironolactone 5% Topical Gel, Adapalene 0.1% Topical Gel - Acne Vulgaris | Phase 2 | Not yet recruiting | Assiut University | 40 | 2026-04-01 | 2026-03-17 |
| A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris. HB0043, Placebo - Acne Vulgaris | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Huaota Biopharmaceutical Co., Ltd. | 21 | 2026-03-27 | 2026-03-04 |
| Safety and Efficacy of Topical AT-004 1% in Participants With Acne Vulgaris (AV) AT-004, Placebo - Acne Vulgaris on the Face | Phase 2 | Completed | Arctic Therapeutics | 63 | 2026-02-02 | 2026-08-19 |
| Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris KR230109 cream 0.025%, KR230109 cream 0.05%, Placebo - Acne Vulgaris | Phase 2 | Not yet recruiting | Jiangxi Kvvit Pharmaceutical Co., Ltd. | 180 | 2026-01-10 | 2026-01-15 |
| Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne MPN-coated engineered Lactobacillus reuteri cream, Plain Lactobacillus reuteri cream, Petrolatum-glycerin cream - Acne | Phase 2 | Recruiting | Shenzhen People's Hospital | 196 | 2025-12-30 | 2026-04-06 |
| A Split-Face Comparative Study of Mono Threads Versus Combination With Plasma Gel for the Treatment of Post-Acne Scars polydioxanone (PDO) mono threads, Mono Threads with Plasma Gel - Acne | Phase 2 / Phase 3 | Enrolling by invitation | Tanta University | 20 | 2025-11-10 | 2026-10-29 |
| Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne Acne mRNA vaccine, Placebo - Acne | Phase 1 / Phase 2 | Recruiting | Sanofi Pasteur, a Sanofi Company | 228 | 2025-07-03 | 2026-07-09 |
| Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense Tibulizumab Dose A, Tibulizumab Dose B, Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Active not recruiting | Zura Bio Inc | 247 | 2025-05-16 | 2026-10-19 |
| The Relationship Between Microbioma Balance and Acne Vulgaris as a New Acne Treatment Standard therapy, HEXBIO, Secretome - Acne Vulgaris | Phase 2 | Not yet recruiting | Universitas Padjadjaran | 64 | 2025-05-01 | 2025-04-13 |
| Efficacy, Safety Profile, and Post-Acne Sequelae of 0.025% Retinoic Acid Cream vs. 0.1% Adapalene Cream in Mild Acne Vulgaris in Fitzpatrick Skin Types III-V retinoic acid cream 0.025%, adapalene cream 0.1% - Acne Vulgaris | Phase 1 / Phase 2 | Completed | Universitas Indonesia | 23 | 2024-11-30 | 2025-06-11 |
| Effectiveness and Safety of Zingiber Officinale Transdermal Patch for Acne Vulgaris; Study of Interleukin 1 and Skin Microbiome tretinoin 0.025% + Z. officinale patch, tretinoin 0.025% cream - Acne Vulgaris | Phase 2 / Phase 3 | Active not recruiting | Hasanuddin University | 26 | 2024-11-03 | 2025-09-15 |
| A Full Face Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Addition with MG-CLR Serum for Acne Treatment Over 12 Weeks. Dermapen 4™ - Acne | Phase 2 / Phase 3 | Unknown | Equipmed USA LLC | 10 | 2024-10-01 | 2024-09-19 |
| Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy Clascoterone 1% Top Cream, Vehicle - Acne Vulgaris | Phase 1 / Phase 2 | Active not recruiting | Stanford University | 18 | 2024-07-22 | 2026-04-30 |
| Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne Acne mRNA vaccine, Placebo - Acne | Phase 1 / Phase 2 | Recruiting | Sanofi Pasteur, a Sanofi Company | 800 | 2024-04-05 | 2026-08-21 |
| Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne N-chlorin e6 triglumine, acne removal surgery - Acne, Photodynamic Therapy | Phase 2 | Unknown | Xiyuan Hospital of China Academy of Chinese Medical Sciences | 46 | 2024-02-01 | 2024-03-15 |
| The Impact of Probiotics on Skin Hydration in Youth with Mild Acne Probiotic, Placebo - Acne Vulgaris, Hydration Acne | Phase 2 | Completed | Lallemand Health Solutions | 58 | 2023-09-04 | 2024-09-20 |
| PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea PF-07038124, Placebo Ointment - Seborrheic Dermatitis, Papulopustular Rosacea | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 32 | 2023-07-19 | 2026-08-14 |
Showing 20 of 155. Sign in to see all of them.
Acne Vulgaris (141) · Dermatitis, Seborrheic (13) · Hyperpigmentation (3) · Rosacea (3) · Inflammation (2) · Acne Conglobata (1) · Adenocarcinoma, Papillary (1) · Alopecia (1) · Anxiety Disorders (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Carcinoma, Basal Cell (1) · Carcinoma, Basosquamous (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Signet Ring Cell (1) · Cicatrix (1)
Skin and Connective Tissue Diseases (155) · Skin Diseases (154) · Acneiform Eruptions (142) · Dermatitis (13) · Skin Diseases, Eczematous (13) · Skin Diseases, Papulosquamous (13) · Pathological Conditions, Signs and Symptoms (6) · Pathologic Processes (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Immune System Diseases (3) · Neoplasms (3) · Pigmentation Disorders (3) · Signs and Symptoms (3)
Doxycycline (8) · Gels (8) · 1-phenyl-3,3-dimethyltriazene (6) · Adapalene (5) · Clascoterone (4) · Isotretinoin (3) · Tretinoin (3) · berdazimer sodium (3) · tazarotene (3) · Benzoyl Peroxide (2) · Clindamycin (2) · Ketoconazole (2) · Omiganan (2) · Red Light (2) · Salicylic Acid (2)
Bausch Health Americas, Inc. (6) · Photocure (6) · Galderma R&D (5) · AOBiome LLC (3) · BioPharmX, Inc. (3) · Braintree Laboratories (3) · Dermira, Inc. (3) · Maruho Co., Ltd. (3) · Mimetica Pty Limited (3) · Novan, Inc. (3) · Oplon-Pure Science Ltd. (3) · University of Michigan (3) · AndroScience Corp (2) · Arcutis Biotherapeutics, Inc. (2) · Assiut University (2)
United States (92) · Canada (15) · Israel (7) · China (6) · Egypt (6) · Germany (5) · Indonesia (5) · Australia (4) · France (4) · Netherlands (4) · Dominican Republic (3) · Iran (3) · Bangladesh (2) · Belgium (2) · Honduras (2)
Anya Loncaric (3) · John J Voorhees, MD (3) · AnnaMarie Daniels (2) · Anya Loncaric, MS (2) · Avner Shemer, M.D. (2) · Benjamin Ungar, MD (2) · David Berk, MD (2) · David Pariser, MD (2) · Jim Pankovich (2) · Jonathan S Dosik, MD (2) · Michael Graeber, MD (2) · Parviz Toossi, M.D. (2) · Aida Lugo-Somolinos, MD (1)
PMID 40377868, PMID 16247244, PMID 18394082, PMID 18532922, PMID 18720689, PMID 21108671, PMID 21572783, PMID 22712470, PMID 23547851, PMID 27272073, PMID 27672413, PMID 32108322, PMID 34674160, PMID 36933926, PMID 37133856, PMID 38466972, PMID 41175336, PMID 41186280, PMID 42242743, PMID 7955470
2025 (3), 2016 (1), 2017 (1), R01AR053542 (1), UM1CA186709 (1), UM1CA186716 (1)